Cargando…

Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients

BACKGROUND: (68)Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([(68)Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandgren, Kristina, Johansson, Lennart, Axelsson, Jan, Jonsson, Joakim, Ögren, Mattias, Ögren, Margareta, Andersson, Martin, Strandberg, Sara, Nyholm, Tufve, Riklund, Katrine, Widmark, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328430/
https://www.ncbi.nlm.nih.gov/pubmed/30631980
http://dx.doi.org/10.1186/s40658-018-0239-2
_version_ 1783386638888468480
author Sandgren, Kristina
Johansson, Lennart
Axelsson, Jan
Jonsson, Joakim
Ögren, Mattias
Ögren, Margareta
Andersson, Martin
Strandberg, Sara
Nyholm, Tufve
Riklund, Katrine
Widmark, Anders
author_facet Sandgren, Kristina
Johansson, Lennart
Axelsson, Jan
Jonsson, Joakim
Ögren, Mattias
Ögren, Margareta
Andersson, Martin
Strandberg, Sara
Nyholm, Tufve
Riklund, Katrine
Widmark, Anders
author_sort Sandgren, Kristina
collection PubMed
description BACKGROUND: (68)Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([(68)Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both in the primary and secondary stages of prostate cancer. The aim of this study was to determine the effective dose and organ doses from injection of [(68)Ga]PSMA-11 in a cohort of low-risk prostate cancer patients. METHODS: Six low-risk prostate cancer patients were injected with 133–178 MBq [(68)Ga]PSMA-11 and examined with four PET/CT acquisitions from injection to 255 min post-injection. Urine was collected up to 4 h post-injection, and venous blood samples were drawn at 45 min, 85 min, 175 min, and 245 min post-injection. Kidneys, liver, lungs, spleen, salivary and lacrimal glands, and total body where delineated, and cumulated activities and absorbed organ doses calculated. The software IDAC-Dose 2.1 was used to calculate absorbed organ doses according to the International Commission on Radiological Protection (ICRP) publication 107 using specific absorbed fractions published in ICRP 133 and effective dose according to ICRP Publication 103. We also estimated the absorbed dose to the eye lenses using Monte Carlo methods. RESULTS: [(68)Ga]PSMA-11 was rapidly cleared from the blood and accumulated preferentially in the kidneys and the liver. The substance has a biological half-life in blood of 6.5 min (91%) and 4.4 h (9%). The effective dose was calculated to 0.022 mSv/MBq. The kidneys received approximately 40 mGy after an injection with 160 MBq [(68)Ga]PSMA-11 while the lacrimal glands obtained an absorbed dose of 0.12 mGy per administered MBq. Regarding the eye lenses, the absorbed dose was low (0.0051 mGy/MBq). CONCLUSION: The effective dose for [(68)Ga]PSMA-11 is 0.022 mSv/MBq, where the kidneys and lacrimal glands receiving the highest organ dose.
format Online
Article
Text
id pubmed-6328430
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-63284302019-01-25 Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients Sandgren, Kristina Johansson, Lennart Axelsson, Jan Jonsson, Joakim Ögren, Mattias Ögren, Margareta Andersson, Martin Strandberg, Sara Nyholm, Tufve Riklund, Katrine Widmark, Anders EJNMMI Phys Original Research BACKGROUND: (68)Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([(68)Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both in the primary and secondary stages of prostate cancer. The aim of this study was to determine the effective dose and organ doses from injection of [(68)Ga]PSMA-11 in a cohort of low-risk prostate cancer patients. METHODS: Six low-risk prostate cancer patients were injected with 133–178 MBq [(68)Ga]PSMA-11 and examined with four PET/CT acquisitions from injection to 255 min post-injection. Urine was collected up to 4 h post-injection, and venous blood samples were drawn at 45 min, 85 min, 175 min, and 245 min post-injection. Kidneys, liver, lungs, spleen, salivary and lacrimal glands, and total body where delineated, and cumulated activities and absorbed organ doses calculated. The software IDAC-Dose 2.1 was used to calculate absorbed organ doses according to the International Commission on Radiological Protection (ICRP) publication 107 using specific absorbed fractions published in ICRP 133 and effective dose according to ICRP Publication 103. We also estimated the absorbed dose to the eye lenses using Monte Carlo methods. RESULTS: [(68)Ga]PSMA-11 was rapidly cleared from the blood and accumulated preferentially in the kidneys and the liver. The substance has a biological half-life in blood of 6.5 min (91%) and 4.4 h (9%). The effective dose was calculated to 0.022 mSv/MBq. The kidneys received approximately 40 mGy after an injection with 160 MBq [(68)Ga]PSMA-11 while the lacrimal glands obtained an absorbed dose of 0.12 mGy per administered MBq. Regarding the eye lenses, the absorbed dose was low (0.0051 mGy/MBq). CONCLUSION: The effective dose for [(68)Ga]PSMA-11 is 0.022 mSv/MBq, where the kidneys and lacrimal glands receiving the highest organ dose. Springer International Publishing 2019-01-11 /pmc/articles/PMC6328430/ /pubmed/30631980 http://dx.doi.org/10.1186/s40658-018-0239-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Sandgren, Kristina
Johansson, Lennart
Axelsson, Jan
Jonsson, Joakim
Ögren, Mattias
Ögren, Margareta
Andersson, Martin
Strandberg, Sara
Nyholm, Tufve
Riklund, Katrine
Widmark, Anders
Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
title Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
title_full Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
title_fullStr Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
title_full_unstemmed Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
title_short Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
title_sort radiation dosimetry of [(68)ga]psma-11 in low-risk prostate cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328430/
https://www.ncbi.nlm.nih.gov/pubmed/30631980
http://dx.doi.org/10.1186/s40658-018-0239-2
work_keys_str_mv AT sandgrenkristina radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT johanssonlennart radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT axelssonjan radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT jonssonjoakim radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT ogrenmattias radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT ogrenmargareta radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT anderssonmartin radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT strandbergsara radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT nyholmtufve radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT riklundkatrine radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT widmarkanders radiationdosimetryof68gapsma11inlowriskprostatecancerpatients